NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in

Status Completed

Clinical Trial Summary

The primary objective of the trial is to determine the feasibility and clinical safety and efficacy of non-invasive inhaled nitric oxide in infants with PPHN without significant pulmonary +-parenchymal disease who would normally receive inhaled nitric oxide only after placement of a tracheal tube and the institution of mechanical ventilation.

Clinical Trial Description

Blending low doses of NO gas with oxygen in the inspiratory limb of mechanical ventilators is an effective method for reducing pulmonary vascular resistance and decreasing extrapulmonary right-to-left shunting at the ductus arteriosus and foramen ovale in many patients with PPHN. However, in some patients with PPHN, sustained elevations of PVR may occur in the absence of or despite improvement in the parenchymal lung disease such that mechanical ventilation is not needed for maintaining adequate gas exchange.

PPN in the absence of pulmonary parenchymal disease or despite improvement in the parenchymal lung disease occurs in a significant subset of newborn infants with hypoxemic respiratory failure. Inhaled NO can be effectively delivered by non-invasive techniques to newborn infants with PPHN, potentially reducing the duration of mechanical ventilation, while safely treating the elevation in pulmonary artery pressure and right-to-left.

A dose of 10-20 ppm measured within the delivery device is sufficient to maintain nasopharyngeal concentrations within a range of 1-10 ppm. My co-authors and I have also reported a series of eleven infants with pulmonary hypertension treated with low dose iNO delivered via nasal cannula after extubation at the 14th Annual CNMC Symposium on ECMO & Advanced Therapies for Respiratory Failure, Keystone, CO, 1998. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Hypertension
Hypertension, Pulmonary
Persistent Fetal Circulation Syndrome
Pulmonary Hypertension

Clinical Trial Details

NCT number	NCT00139217
Study type	Interventional
Source	Emory University
Contact
Status	Completed
Phase	N/A
Start date	August 2005
Completion date	September 2007

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01950585` - Hydroxyurea in Pulmonary Arterial Hypertension	Early Phase 1
Completed	`NCT00527163` - Role of Nitric Oxide in Malaria
Completed	`NCT03649932` - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing	Phase 1
Recruiting	`NCT04554160` - Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Completed	`NCT01894035` - Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
Not yet recruiting	`NCT04083729` - Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy	N/A
Completed	`NCT02216279` - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension	Phase 2
Completed	`NCT02821156` - Study on the Use of Inhaled NO (iNO)	N/A
Terminated	`NCT02246348` - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)	N/A
Terminated	`NCT02243111` - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound	N/A
Recruiting	`NCT01913847` - Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension	Phase 3
Completed	`NCT06240871` - Contrast Enhanced PA Pressure Measurements
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT02377934` - Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
Recruiting	`NCT01091012` - Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension	Phase 3
Completed	`NCT01463514` - Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension	N/A
Completed	`NCT01484899` - Smoking: a Risk Factor for Pulmonary Arterial Hypertension?	N/A
Completed	`NCT00739375` - The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.	Phase 1
Completed	`NCT02275793` - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms